COMMUNIQUÉS West-GlobeNewswire

MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million
02/04/2026
MediWound Reports BARDA Contract Award to Vericel for NexoBrid ® Valued at up to $197 Million YAVNE, Israel, April 2, 2026 — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics [...]
AbbVie IBD Scholarship Program Marks 15 Years: Applications Open for 2026
02/04/2026
Celebrating 15 years of impact, the program supports Canadian students with Crohn’s disease or ulcerative colitis with fifteen $5,000 scholarships in 2026 TORONTO, April 02, 2026 (GLOBE NEWSWIRE) -- Crohn’s and Colitis [...]
Liv Hospital Highlights Hospital-Based Stem Cell Infrastructure During Autism Awareness Month
02/04/2026
LivMedCell’s Ministry of Health-licensed cGMP framework supports physician-led evaluation and multidisciplinary clinical coordination Photo: Liv Hospital Ulus via FL Comms ISTANBUL, April 02, 2026 (GLOBE NEWSWIRE) -- [...]
EssilorLuxottica acquires a stake in Top Charoen, reinforcing its presence in Thailand
02/04/2026
EssilorLuxottica acquires a stake in Top Charoen, reinforcing its presence in Thailand Paris, France and Bangkok, Thailand (2 April 2026) – EssilorLuxottica and Top Charoen today announced that they have closed a [...]
EssilorLuxottica entre au capital de Top Charoen pour renforcer sa présence en Thailande
02/04/2026
EssilorLuxottica entre au capital de Top Charoen pour renforcer sa présence en Thailande Paris, France et Bangkok, Thaïlande (2 avril 2026) – EssilorLuxottica et Top Charoen annoncent aujourd’hui la finalisation d’une [...]
Le programme de bourses d'études MII d’AbbVie fête ses 15 ans : les candidatures sont ouvertes pour 2026
02/04/2026
Depuis 15 ans, le programme soutient des étudiants canadiens atteints de la maladie de Crohn ou de colite ulcéreuse, en octroyant quinze bourses d'études de 5 000 $ TORONTO, 02 avr. 2026 (GLOBE NEWSWIRE) -- Crohn et [...]
BioCardia Files Request for Meeting With FDA to Discuss Accelerated Approval Pathway for CardiAMP® System in Ischemic Heart Failure
02/04/2026
SUNNYVALE, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today [...]
Medicana Health Group Marks World Autism Awareness Day with a Call for Inclusion, Earlier Recognition and Family-Centered Support
02/04/2026
Medicana Ataköy Hospital in Istanbul highlights multidisciplinary care, responsible public dialogue and quality-led healthcare standards Photo: Medicana Ataköy Hospital via FL Comms ISTANBUL, April 02, 2026 (GLOBE [...]
Curonix LLC Announces Expanded Reimbursement Coverage for Freedom® Peripheral Nerve Stimulator (PNS) System, Providing Access To An Additional 27 Million Covered Lives Nationwide
02/04/2026
POMPANO BEACH, Fla., April 02, 2026 (GLOBE NEWSWIRE) -- Curonix LLC, a leading medical technology company dedicated to relieving chronic pain, today announced significant reimbursement milestones for its Freedom ® [...]
Visory Health Ranks Among Top U.S. Prescription Cards Providing Millions of Americans Access to Affordable Medications
02/04/2026
The discount card platform is disrupting a multi-billion-dollar industry in just four years ESTERO, Fla., April 02, 2026 (GLOBE NEWSWIRE) -- Visory Health , a patient-first health tech prescription platform that is [...]
EYLEA HD® (aflibercept) Approved by FDA as First and Only Injectable Anti-VEGF with Dosing Intervals Up to 5 Months for Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME)
02/04/2026
Approval is based on 96-week data from 2 pivotal trials showing majority of EYLEA HD patients maintained their visual and anatomic improvements with extended dosing intervals New EYLEA HD dosing regimen allows patients [...]
GENFIT Reports Full-Year 2025 Financial Results and Provides Corporate Update
02/04/2026
2025 financial highlights: Cash and cash equivalents totaled €101.1 million as of December 31, 2025 Revenues amounting to €65.4 million for the period ended December 31, 2025, including €43.6 million in milestones and € [...]
GENFIT : Résultats financiers annuels 2025 et point sur les activités de la Société
02/04/2026
Faits financiers marquants de 2025 : Trésorerie et équivalents de trésorerie s’élevant à 101.1 millions d’euros au 31 décembre 2025 Chiffre d’affaires s’élevant à 65.4 millions d’euros au 31 décembre 2025, dont 43.6 [...]
Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections
02/04/2026
MALVERN, Pa., April 02, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for [...]
Cylinder Health launches Stool Scan to innovate and standardize one of GI care’s most subjective signals
02/04/2026
Clinically validated image recognition removes patient guesswork, captures multivariate stool data, and supports earlier, more precise assessment of GI patterns CHICAGO, April 02, 2026 (GLOBE NEWSWIRE) -- Cylinder [...]
Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs
02/04/2026
SAN DIEGO and SUZHOU, China, April 02, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene” or the “Company”) (Nasdaq: ADAG), a company committed to transforming the discovery and development of novel antibody-based [...]
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)
02/04/2026
Phase 1 study of INCA33890 and muzastotug expected to begin in 2026 in 3L MSS CRC patients with and without liver metastases Study will be sponsored and conducted by Incyte; Adagene to provide clinical supply of [...]
Plus Therapeutics Secures Highmark Coverage for CNSide® CSF Assay, Expanding Reimbursement to ~75 Million Covered Lives
02/04/2026
HOUSTON, April 02, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV ) (“Plus” or the “Company”), today announces a new payer coverage agreement with [...]
Commure Introduces Dictation: AI-Powered Clinical Voice, Now at the Cursor
02/04/2026
The new extension brings Commure’s Ambient AI to every text field, replacing legacy dictation systems with a single, seamless voice platform. MOUNTAIN VIEW, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- Commure today [...]

Pages